Trade Summary

3 days ago, Rodman David Malcom, serving as Chief Medical Officer at Mineralys Therapeutics, Inc. (MLYS), sold 2,171 shares at $30.30 per share, for a total transaction value of $65,781.30. Following this transaction, Rodman David Malcom now holds 57,733 shares of MLYS.

This sale represents a 3.62% decrease in Rodman David Malcom's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, July 9, 2026 and publicly disclosed via SEC Form 4 filing on Friday, July 10, 2026 at 7:15 PM ET, 1 day after the trade was made.

Mineralys Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.